Johnson & Johnson’s second-quarter profit beat Wall Street projections on strong pharmaceutical sales, while the company cut its full-year forecast to account for a spate of recent acquisitions.
See Also
Johnson & Johnson (NYSE:JNJ)Johnson & Johnson Stock Price | JNJ Stock Quote, News, and History | Markets InsiderJohnson & Johnson (NYSE:JNJ) Stock Forecast & Analyst Predictions - Simply Wall StCheck out Johnson & Johnson's stock price (JNJ) in real timeAdjusted earnings for the quarter were $2.82 a share, the New Brunswick, New Jersey-based company said Wednesday in a statement, beating analysts’ average estimate by 11 cents. While drug sales were slightly ahead and medical device revenue fell a bit short, spending on research and development was below expectations.
